Amphastar Pharmaceuticals In (AMPH) — 13F Filings Explorer (Q2 2026)

AMPH ranks #2834 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

215 institutions disclose a position in AMPH, but none treat it as a major bet — even Bridge City Capital, LLC, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

SteelPeak Wealth, LLC has added to its AMPH position for two straight quarters, increasing it by $307.8K to reach $1.3M today.

CX Institutional has trimmed its AMPH position for two straight quarters, cutting it by $43.0K while still holding $15.0K.

AMPH is down 2.1% today, but institutions show net buying of $17.3M this quarter — a divergence between today's price move and the underlying institutional flow.

AMPH posted net income of $78.5M over the trailing twelve months, and currently trades at a P/E of 15.9.

• Profitable — net income of $78.5M over the trailing twelve months
• Revenue grew 1.0% year over year
• Net income declined year over year, from $134.7M to $78.5M
• Generated $156.1M in positive operating cash flow
• Current ratio of 4.02x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.07x equity — within a conventional range